160
Participants
Start Date
October 31, 2025
Primary Completion Date
August 1, 2027
Study Completion Date
August 1, 2028
Ervebo
Ebola Zaire vaccine (rVSV∆G-ZEBOV-GP, live, attenuated) ≥ 72 million PFU, composed of the Indiana strain of recombinant vesicular stomatitis virus (rVSV) with a deletion of the envelope glycoprotein (G) of VSV replaced by the surface glycoprotein (GP) of the Kikwit 1995 strain of Ebola virus Zaire (ZEBOV)
Inmazeb
Inmazeb (REGN-EB3), developed by Regeneron, is a cocktail of 3 neutralising humanised mAbs directed against 3 epitopes of the EBOV GP (atoltivimab, maftivimab and odesivimab). It is indicated for the treatment of EVD in adult patients (including pregnant women) and in children, including neonates born to mothers with confirmed EVD.
National Institute for Biomedical Research (INRB), Kinshasa
Guinea Centre for Research and Training in Infectious Diseases (CERFIG), Conakry
National Public Health Institute of Liberia, Monrovia
University of Sierra Leone College of Medicine and Allied Health Sciences, Freetown
Collaborators (1)
Alliance for International Medical Action
OTHER
Centre de Recherche et de Formation en Infectiologie de Guinée (CERFIG)
UNKNOWN
Medecins Sans Frontieres, Netherlands
OTHER
Barcelona Institute for Global Health
OTHER
University of Bordeaux
OTHER
INSERM UMR S 1136
OTHER
Agence Nationale de Sécurité Sanitaire de Guinée (ANSS)
UNKNOWN
National Institute for Biomedical Research DRC
UNKNOWN
Cheikh Anta Diop University, Senegal
OTHER
PACCI Program
OTHER
The PANdemic preparedness plaTform for Health and Emerging infectious Response
UNKNOWN
University of Sierra Leone College of Medicine and Allied Health Sciences
UNKNOWN
National Public Health Institute of Liberia
UNKNOWN
ANRS, Emerging Infectious Diseases
OTHER_GOV